Abstract
Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin. The results of this study will help define the role of this novel agent in the management of advanced pancreatic cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1295-1302 |
| Number of pages | 8 |
| Journal | Future Oncology |
| Volume | 15 |
| Issue number | 12 |
| DOIs | |
| State | Published - Apr 1 2019 |
Fingerprint
Keywords
- BBI-608
- cancer stem cells
- CanStem111P
- napabucasin
- pancreatic adenocarcinoma
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
CanStem111P trial : A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. / Sonbol, Mohamad Bassam; Ahn, Daniel; Goldstein, David; Okusaka, Takuji; Tabernero, Josep; Macarulla, Teresa; Reni, Michele; Li, Chung Pin; O'Neil, Bert; Van Cutsem, Eric; Bekaii-Saab, Tanios.
In: Future Oncology, Vol. 15, No. 12, 01.04.2019, p. 1295-1302.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - CanStem111P trial
T2 - A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine
AU - Sonbol, Mohamad Bassam
AU - Ahn, Daniel
AU - Goldstein, David
AU - Okusaka, Takuji
AU - Tabernero, Josep
AU - Macarulla, Teresa
AU - Reni, Michele
AU - Li, Chung Pin
AU - O'Neil, Bert
AU - Van Cutsem, Eric
AU - Bekaii-Saab, Tanios
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin. The results of this study will help define the role of this novel agent in the management of advanced pancreatic cancer.
AB - Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin. The results of this study will help define the role of this novel agent in the management of advanced pancreatic cancer.
KW - BBI-608
KW - cancer stem cells
KW - CanStem111P
KW - napabucasin
KW - pancreatic adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=85065084658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065084658&partnerID=8YFLogxK
U2 - 10.2217/fon-2018-0903
DO - 10.2217/fon-2018-0903
M3 - Article
VL - 15
SP - 1295
EP - 1302
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 12
ER -